Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer

被引：0

作者：

Toffart, A. -C. ^{[1
,2
]}

Sakhri, L. ^{[1
,2
]}

Moro-Sibilot, D. ^{[1
,2
]}

机构：

[1] Ctr Hosp Univ A Michallon, UM Oncol Thorac, F-38043 Grenoble 9, France

[2] Univ Grenoble 1, Inst A Bonniot, INSERM, U823, Grenoble, France

来源：

REVUE DE PNEUMOLOGIE CLINIQUE | 2013年 / 69卷 / 02期

关键词：

EML4-ALK; Lung cancer; Crizotinib; Targeted therapy; Never smoker; Adenocarcinoma; EML4-ALK FUSION GENE; KINASE INHIBITOR; RESISTANCE; REARRANGEMENT; MUTATIONS; EFFICACY; MET; NPM;

D O I：

10.1016/j.pneumo.2012.11.010

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Crizotinib is a small orally-administered ALK inhibitor for patients with non-small cell lung cancer with EML4-ALK rearrangement (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase). This fusion gene is detected with a break apart fluorescence in situ hybridization (FISH) assay. Phase I to III trials have shown an interesting disease control rate and acceptable tolerability. Crizotinib is available in France under temporary use authorization. New potentially effective therapeutics in ALK-positive NSCLC are being developed. (C) 2013 Elsevier Masson SAS. All rights reserved.

引用

页码：111 / 116

页数：6

共 50 条

[1] Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers
Chuang, Jody C.
Neal, Joel W.
[J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (05) : 639 - 641
[2] Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer
Deng, Huiyan
Li, Bin
Li, Lina
Peng, Jingcui
Lv, Tongshuai
Liu, Yueping
Ding, Cuimin
[J]. PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
[3] Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer
Kang, Jin
Chen, Hua-Jun
Zhang, Xu-Chao
Su, Jian
Zhou, Qing
Tu, Hai-Yan
Wang, Zhen
Wang, Bin-Chao
Zhong, Wen-Zhao
Yang, Xue-Ning
Chen, Zhi-Hong
Ding, Yan
Wu, Xue
Wang, Mei
Fu, Jian-Gang
Yang, Zhenfan
Zhang, Xian
Shao, Yang W.
Wu, Yi-Long
Yang, Jin-Ji
[J]. THORACIC CANCER, 2018, 9 (09) : 1093 - 1103
[4] Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Nishio, Makoto
Kim, Dong-Wan
Wu, Yi-Long
Nakagawa, Kazuhiko
Solomon, Benjamin J.
Shaw, Alice T.
Hashigaki, Satoshi
Ohki, Emiko
Usari, Tiziana
Paolini, Jolanda
Polli, Anna
Wilner, Keith D.
Mok, Tony
[J]. CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 691 - 700
[5] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
Rosado-Buzzo, A.
Garcia-Mollinedo, L.
Luna-Casas, G.
Mould-Quevedo, J. F.
Gutierrez-Ardila, M., V
Vargas Zea, N.
[J]. VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
[6] Crizotinib: A New Treatment Option for ALK-Positive Non-Small Cell Lung Cancer
O'Bryant, Cindy L.
Wenger, Sarah D.
Kim, Miryoung
Thompson, Lisa A.
[J]. ANNALS OF PHARMACOTHERAPY, 2013, 47 (02) : 189 - 197
[7] Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients
Shaohua Cui
Yizhuo Zhao
Aiqin Gu
Xiaoxiao Ge
Yanyan Song
Wei Zhang
Yuqing Lou
Lili Dong
Baohui Han
Liyan Jiang
[J]. Medical Oncology, 2015, 32
[8] ESTIMATING THE BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ARGENTINA
Wang, B.
Furnback, W.
Xuan, J.
[J]. VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
[9] CLINICAL EXPERIENCE WITH CRIZOTINIB IN SPECIAL POPULATIONS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Ahn, M-J
Crino, L.
Solomon, Ben
Zhou, Caicun
Ou, Sai-hong I.
Selaru, P.
Cohen, D. P.
Bartlett, C. H.
Kim, Dong-wan
[J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S491
[10] Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
Kim, E.
Usari, T.
Polli, A.
Lewis, I.
Wilner, K.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134

← 1 2 3 4 5 →